Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026

Climb Bio, Inc. (NASDAQ: CLYM) will present new clinical data for its CLYM116 and budoprutug programs targeting three immune-mediated kidney diseases at the American Society of Nephrology Kidney Week 2026, scheduled for October 21-25, 2026, in Denver, Colorado.